PL2838539T3 - Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych - Google Patents
Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznychInfo
- Publication number
- PL2838539T3 PL2838539T3 PL13714917T PL13714917T PL2838539T3 PL 2838539 T3 PL2838539 T3 PL 2838539T3 PL 13714917 T PL13714917 T PL 13714917T PL 13714917 T PL13714917 T PL 13714917T PL 2838539 T3 PL2838539 T3 PL 2838539T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- neurological disorders
- estrogenic components
- estrogenic
- components
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12164741.6A EP2653163A1 (en) | 2012-04-19 | 2012-04-19 | Estrogenic components for use in the treatment of neurological disorders |
| EP13714917.5A EP2838539B1 (en) | 2012-04-19 | 2013-04-08 | Estrogenic derivatives for use in the treatment of neurological disorders. |
| PCT/EP2013/057279 WO2013156329A1 (en) | 2012-04-19 | 2013-04-08 | Estrogenic components for use in the treatment of neurological disorders. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2838539T3 true PL2838539T3 (pl) | 2018-01-31 |
Family
ID=48050711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13714917T PL2838539T3 (pl) | 2012-04-19 | 2013-04-08 | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9238035B2 (pl) |
| EP (2) | EP2653163A1 (pl) |
| JP (1) | JP6139662B2 (pl) |
| CN (1) | CN104379148B (pl) |
| AU (1) | AU2013248481B2 (pl) |
| CA (1) | CA2869902C (pl) |
| CY (1) | CY1119603T1 (pl) |
| DK (1) | DK2838539T3 (pl) |
| ES (1) | ES2647111T3 (pl) |
| HR (1) | HRP20171627T1 (pl) |
| HU (1) | HUE034902T2 (pl) |
| LT (1) | LT2838539T (pl) |
| NO (1) | NO2838539T3 (pl) |
| PL (1) | PL2838539T3 (pl) |
| PT (1) | PT2838539T (pl) |
| RS (1) | RS56595B1 (pl) |
| RU (1) | RU2627846C2 (pl) |
| SI (1) | SI2838539T1 (pl) |
| SM (1) | SMT201700531T1 (pl) |
| WO (1) | WO2013156329A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012164096A1 (en) | 2011-06-01 | 2012-12-06 | Estetra S.A. | Process for the production of estetrol intermediates |
| BR112013030833B1 (pt) | 2011-06-01 | 2019-09-03 | Estetra S A | processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| WO2016187558A2 (en) * | 2015-05-20 | 2016-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method to improve neurologic outcomes in temperature managed patients |
| RS57328B1 (sr) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu |
| NZ737945A (en) * | 2015-06-18 | 2023-06-30 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| WO2016203044A1 (en) * | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN107260712A (zh) * | 2017-06-22 | 2017-10-20 | 中国人民解放军第三军医大学 | 奥培米芬在制备促进髓鞘形成和再生的药物中的应用 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CR20200486A (es) | 2018-04-19 | 2021-01-27 | Estetra Sprl | Compuestos y sus usos para aliviar los síntomas asociados a la menopausa |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| CN113243332B (zh) * | 2020-02-07 | 2023-07-28 | 上海市东方医院（同济大学附属东方医院） | 一种广泛脑区神经元树突发育障碍动物模型的制备与应用 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| AU2003274943A1 (en) | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | Use of estetrol and analogues for treating or preventing cardiovascular pathologies, in particular atherosclerosis |
| AU2003274946A1 (en) * | 2002-06-11 | 2003-12-22 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| AU2006294662A1 (en) * | 2005-09-26 | 2007-04-05 | The Regents Of The University Of California | Estriol therapy for autoimmune and neurodegenerataive diseases and disorders |
| EP1971344B1 (en) * | 2006-01-09 | 2010-09-22 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
| US8367647B2 (en) * | 2007-06-21 | 2013-02-05 | Pantarhei Bioscience B.V. | Treatment of meconium aspiration syndrome with estrogens |
| AU2008325211B2 (en) * | 2007-11-06 | 2014-11-13 | Signal Coordinating Therapy, Inc. | Compositions and methods for treating Parkinson's disease and related disorders |
| CN101884638B (zh) * | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
-
2012
- 2012-04-19 EP EP12164741.6A patent/EP2653163A1/en not_active Withdrawn
-
2013
- 2013-04-08 AU AU2013248481A patent/AU2013248481B2/en active Active
- 2013-04-08 DK DK13714917.5T patent/DK2838539T3/da active
- 2013-04-08 PL PL13714917T patent/PL2838539T3/pl unknown
- 2013-04-08 RS RS20171122A patent/RS56595B1/sr unknown
- 2013-04-08 RU RU2014145800A patent/RU2627846C2/ru active
- 2013-04-08 HU HUE13714917A patent/HUE034902T2/hu unknown
- 2013-04-08 SM SM20170531T patent/SMT201700531T1/it unknown
- 2013-04-08 LT LTEP13714917.5T patent/LT2838539T/lt unknown
- 2013-04-08 HR HRP20171627TT patent/HRP20171627T1/hr unknown
- 2013-04-08 ES ES13714917.5T patent/ES2647111T3/es active Active
- 2013-04-08 PT PT137149175T patent/PT2838539T/pt unknown
- 2013-04-08 CA CA2869902A patent/CA2869902C/en active Active
- 2013-04-08 US US14/395,465 patent/US9238035B2/en active Active
- 2013-04-08 NO NO13714917A patent/NO2838539T3/no unknown
- 2013-04-08 JP JP2015506173A patent/JP6139662B2/ja active Active
- 2013-04-08 EP EP13714917.5A patent/EP2838539B1/en active Active
- 2013-04-08 WO PCT/EP2013/057279 patent/WO2013156329A1/en not_active Ceased
- 2013-04-08 SI SI201330825T patent/SI2838539T1/sl unknown
- 2013-04-08 CN CN201380020555.6A patent/CN104379148B/zh active Active
-
2017
- 2017-11-14 CY CY20171101193T patent/CY1119603T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2838539T (lt) | 2017-11-27 |
| RS56595B1 (sr) | 2018-02-28 |
| WO2013156329A1 (en) | 2013-10-24 |
| US20150133419A1 (en) | 2015-05-14 |
| AU2013248481A1 (en) | 2014-10-30 |
| CY1119603T1 (el) | 2018-04-04 |
| PT2838539T (pt) | 2017-11-15 |
| EP2838539B1 (en) | 2017-08-16 |
| HRP20171627T1 (hr) | 2017-12-01 |
| DK2838539T3 (da) | 2017-11-27 |
| ES2647111T3 (es) | 2017-12-19 |
| RU2014145800A (ru) | 2016-06-10 |
| SI2838539T1 (sl) | 2017-12-29 |
| CN104379148A (zh) | 2015-02-25 |
| RU2627846C2 (ru) | 2017-08-14 |
| US9238035B2 (en) | 2016-01-19 |
| CA2869902C (en) | 2019-07-02 |
| AU2013248481B2 (en) | 2017-02-16 |
| EP2838539A1 (en) | 2015-02-25 |
| EP2653163A1 (en) | 2013-10-23 |
| JP6139662B2 (ja) | 2017-05-31 |
| CN104379148B (zh) | 2017-08-25 |
| SMT201700531T1 (it) | 2018-01-11 |
| NO2838539T3 (pl) | 2018-01-13 |
| JP2015514731A (ja) | 2015-05-21 |
| CA2869902A1 (en) | 2013-10-24 |
| HUE034902T2 (hu) | 2018-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283943B1 (en) | Use of pyrazolopyrimidine derivatives for the treatment of p13k associated disorders | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| PT2838539T (pt) | Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos. | |
| HUE039687T2 (hu) | Kompozíciók, amelyek alkalmazhatók KIT-tel kapcsolatos rendellenességek kezelésében való alkalmazásra | |
| BR112014013843A2 (pt) | uso de dispositivos para o tratamento de doenças neurológicas | |
| LT2925757T (lt) | Junginiai ir kompozicijos, skirti parazitinių ligų gydymui | |
| IL225668A (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| EP2869833A4 (en) | TREATMENT OF INFLAMMATORY SKIN DISORDERS | |
| IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
| SMT201600395B (it) | Derivati di pantotenato per il trattamento di disturbi neurologici | |
| ZA201504065B (en) | Therapeutic agent for keratoconjunctive disorders | |
| ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
| IL234412B (en) | The iloperidone metabolite for use in the treatment of psychiatric diseases | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| PL2861568T3 (pl) | Aminy trzeciorzędowe do zastosowania w leczeniu zaburzeń serca | |
| ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
| GB201303721D0 (en) | Compositions for treatment of sleep disorders | |
| EP2970118A4 (en) | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | |
| GB201201779D0 (en) | Treatment of inflammatory disorders |